Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Contributeurs/tricesJanssen, Jeroen; Löwenberg, Bob; Manz, Markus ; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves ; Deeren, Dries; Efthymiou, Anna ; Gjertsen, Bjørn-Tore ; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie ; Jie, Asiong ; Jongen-Lavrencic, Mojca; Klein, Saskia; Klift, Marjolein van der ; Kuball, Jürgen; Lammeren-Venema, Danielle van; Legdeur, Marie-Cecile; Loosdrecht, Arjan van de; Maertens, Johan ; Kooy, Marinus van Marwijk; Moors, Ine ; Nijziel, Marten; Obbergh, Florence van; Oosterveld, Margriet; Pabst, Thomas; Poel, Marjolein van der; Sinnige, Harm; Spertini, Olivier ; Terpstra, Wim; Tick, Lidwine; Velden, Walter van der; Vekemans, Marie-Christiane ; Vellenga, Edo; Weerdt, Okke de; Westerweel, Peter; Stüssi, Georg; Norden, Yvette van; Ossenkoppele, Gert
Publié dansCancers, vol. 13, no. 4, 672
Date de publication2021-02-07
Date de mise en ligne2021-02-07
Résumé
Mots-clés
- AML
- Aminopeptidase inhibitor
- Clinical trial
- Elderly
- High-risk MDS
- Tosedostat
Structure d'affiliation
Citation (format ISO)
JANSSEN, Jeroen et al. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. In: Cancers, 2021, vol. 13, n° 4, p. 672. doi: 10.3390/cancers13040672
Fichiers principaux (1)
Article (Published version)
Fichiers secondaires (1)
Identifiants
- PID : unige:159031
- DOI : 10.3390/cancers13040672
- PMID : 33562393
- PMCID : PMC7914531
URL commercialhttps://www.mdpi.com/2072-6694/13/4/672
ISSN du journal2072-6694